Novo Nordisk weighs diabetes drug's use in fatty liver disease
COPENHAGEN (Reuters) - Novo Nordisk is looking into recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease, a hot area for pharmaceutical development.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Clinical Trials | Diabetes | Endocrinology | Fatty Liver Disease (FLD) | Health | Liver | Liver Disease | Urology & Nephrology | Victoza